Business context and reporting period
Important identity note: The supplied filing is NorthView Acquisition Corp.’s Form 10-K for the fiscal year ended December 31, 2022—not an operating-company 10-K filed by Profusa, Inc. NorthView was a blank-check SPAC seeking a healthcare-focused business combination. It signed a merger agreement with Profusa on November 7, 2022; the proposed transaction had not closed when this filing was issued on March 3, 2023.
Financial performance and position
| Metric | 2022 | Comparable period |
|---|---|---|
| Operating revenue | None | None; company had not commenced operations |
| Net income | $7.17 million | $0.30 million, April 19–December 31, 2021 |
| Interest income on trust investments | $2.58 million | $6,461 |
| Gain from change in warrant fair value | $6.36 million | $597,567 |
| Formation and operating costs | $1.27 million | $45,047 |
| Income tax provision | $499,211 | None |
| Cash used in operating activities | $581,189 | $662,393 |
| Cash outside trust at year-end | $193,486 | $741,228 |
| Trust assets at year-end | $194.22 million; $10.20 per public share | $191.65 million; $10.10 per public share |
| Debt | No long-term debt or outstanding working-capital loans | — |
The reported profit was driven by trust interest and a non-cash gain from revaluing warrant liabilities, not operating activity. The warrant liability fell to $857,787 from $7.22 million. The company reported approximately $0.2 million of working capital. Operating margins are not meaningful because there was no revenue.
Material changes and transaction terms
- Trust assets increased to $194.22 million from $191.65 million; the redemption value rose to $10.20 per public share from $10.10.
- The proposed Profusa combination values Profusa at $155 million before the transaction, using an assumed NorthView share value of $10.00. Profusa stockholders may receive up to 3.875 million additional shares subject to revenue and share-price milestones.
- The revenue thresholds described for earnout shares are $5.1 million for fiscal 2023 and $73.1 million for fiscal 2024. These are transaction earnout conditions, not general operating guidance.
- The transaction was subject to minimum available cash, regulatory approvals and both companies’ stockholder approvals; completion was not assured.
Liquidity, outlook and risks
- NorthView had until March 22, 2023 to complete a business combination under its then-current deadline. A March 10, 2023 vote was planned to seek an extension, potentially through December 22, 2023. Failure to complete a transaction or obtain an extension could require liquidation and redemption of public shares.
- Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern if a business combination was not completed by the deadline. The audited statements were not adjusted for a possible liquidation.
- Cash available outside the trust was limited, and the sponsor and insiders were not obligated to provide working-capital loans. The filing reports no long-term debt or off-balance-sheet arrangements.
- Risks include transaction failure, redemptions reducing cash available to close, difficulty obtaining additional financing, competition for targets, conflicts of interest, and possible creditor claims against trust assets. The filing also discusses potential effects of COVID-19, the Russia-Ukraine war and the new 1% federal excise tax on certain stock repurchases.
- The auditor issued an unqualified opinion on the financial statements with a going-concern explanatory paragraph. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal controls.
Most important facts for investors to verify
- Confirm the issuer and scope: this is NorthView’s SPAC filing, not Profusa’s operating-company financial statements.
- Check subsequent filings for the extension vote outcome, merger status, redemption levels, closing cash and any financing arrangements.
- Review Profusa’s audited operating results, cash needs, product and regulatory status, and the basis for the merger’s revenue milestones; these are not provided in this filing.
- Assess potential dilution from earnout shares, rights, warrants, financing securities and the business-combination marketing fee, which was amended to be partly cash and partly equity.
- Consider that reported net income largely reflects interest and warrant remeasurement rather than revenue-generating operations, alongside the going-concern warning and limited cash outside the trust.